The Correlation of KRAS Gene Expression and P53 Immunoexpression In Colorectal Adenocarcinoma
Keywords:KRAS, p53, Adenocarcinoma Colorectal (ADCCR)
BACKGROUND: Colorectal Adenocarcinoma (ADCCR) is the third most cancer not only in the world but also in Indonesia. There were 623 cases of ADCCR at Dr Hasan Sadikin hospital within 2015-2017. Both KRAS and TP53 mutation are known as genes which involve in carcinogenesis through the same pathway, namely the chromosomal instability pathway. In West Java, researches focusing on mutation KRAS and p53 also a correlation between both biomarkers among ADCCR patients are still limited.
AIM: Therefore, this research aimed to perceive a correlation between KRAS gene expression with p53 immunoexpression in ADCCR.
METHODS: Cross section research design was performed to 62 cases of ADCCR as paraffin block taken from 4 hospitals in West Java, including Dr Hasan Sadikin hospital Bandung, Santosa hospital Bandung, Borromeus hospital Bandung and Syamsudin hospital Sukabumi from January 1st 2014 to 31s November 2018. KRAS mutation gene data taken from secondary data at molecular laboratory in Ciptomangunkusumo Hospital Jakarta and Dr Sardjito Hospital Jogjakarta, while the detection of p53 immunoexpression data using immunohistochemical staining was carried out in the Laboratorium of Anatomical Pathology of Padjadjaran University (Dr Hasan Sadikin Hospital). All data were analysed using Chi-Square test with p-value < 0,05 of significant level then proceeded with Stata ver.11 for windows.
RESULTS: The results of this study showed that KRAS gene expressions from 62 sample consist of 39 wild type KRAS (62.39%) and 23 mutant KRAS (37.1%). The p53 immunoexpression consists of 27 negative cases (non-mutant p53) and 35 mutant p53, which includes 10 cases as focal expression (16.33%) and 25 cases as diffuse expressions (40.33%). There is a significant association between KRAS gene expression and p53 immunoexpressions in ADCCR (p = 0.04), with mild positive correlation (Rho 0.28).
CONCLUSION: This study concluded that KRAS and p53 mutations are involved in carcinogenesis, and the p53 mutation is a more dominant risk factor than KRAS mutation among West Java people. P53 mutations with diffuse pattern tend to express mutant KRAS while p53 negative and having a focal pattern tend to express wt KRAS.
Plum Analytics Artifact Widget Block
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. World Health Organization; 2010:131-181.
Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates. Experimental and molecular pathology. 2017; 102(3): 475-83. https://doi.org/10.1016/j.yexmp.2017.05.005 PMid:28506769
Kementrian Kesehatan RI. Panduan Penatalaksanaan Kanker kolorektal. 2015; 1-67.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593
Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumour progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Medical Sciences. 2018; 6(2):31. https://doi.org/10.3390/medsci6020031 PMid:29652830 PMCid:PMC6024750
Kumar V, Abbas AK, Aster JC. Robbins basic pathology. ed-10. Elsevier Health Sciences; 2017:261-71.
Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway?. Gastroenterology and Hepatology from bed to bench. 2012; 5(2):71-5.
Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World journal of gastroenterology: WJG. 2012; 18(37):5171
Sui X, Zhu J, Tang H, Wang C, Zhou J, Han W, Wang X, Fang Y, Xu Y, Li D, Chen R. p53 controls colorectal cancer cell invasion by inhibiting the NF-ÎºB-mediated activation of Fascin. Oncotarget. 2015; 6(26):22869. https://doi.org/10.18632/oncotarget.5137 PMid:26362504 PMCid:PMC4673205
Chaar I, Amara S, Elamine OE, Khiari M, Ounissi D, Khalfallah T, Mzabi S, Bouraoui S. Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma. Tumor Biology. 2014; 35(2):1439-49. https://doi.org/10.1007/s13277-013-1198-9 PMid:24065196 PMCid:PMC3932170
Levi M, Prayogi G, Sastranagara F, Sudianto E, Widjajahakim G, Gani W, Mahanadi A, Agnes J, Khairunisa BH, Utomo AR. Clinicopathological associations of K-RAS and N-RAS mutations in Indonesian colorectal cancer cohort. Journal of gastrointestinal cancer. 2018; 49(2):124-31. https://doi.org/10.1007/s12029-016-9901-x PMid:28044264
Van Cutsem E, Kohne CH, LÃ¡ng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29(15):2011-9. https://doi.org/10.1200/JCO.2010.33.5091 PMid:21502544
Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer research. 2011; 71(23):7168-75. https://doi.org/10.1158/0008-5472.CAN-11-0459 PMid:21983037 PMCid:PMC3320147
Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. The Journal of pathology. 2010; 222(2):129-37. https://doi.org/10.1002/path.2748 PMid:20662002
Ross JS. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Archives of pathology & laboratory medicine. 2012; 136(10):1298-307. https://doi.org/10.5858/arpa.2011-0478-RA PMid:22272560
Al-Kuraya KS. KRAS and TP53 mutations in colorectal carcinoma. Saudi journal of gastroenterology. 2009; 15(4):21-7. https://doi.org/10.4103/1319-3767.56087 PMid:19794264 PMCid:PMC2981835
MÃ¡rmol I, SÃ¡nchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. International journal of molecular sciences. 2017; 18(1):197. https://doi.org/10.3390/ijms18010197 PMid:28106826 PMCid:PMC5297828
Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. International journal of molecular sciences. 2012; 13(10):12153-68. https://doi.org/10.3390/ijms131012153 PMid:23202889 PMCid:PMC3497263
Nyiraneza C, Jouret-Mourin A, Kartheuser A, Camby P, Plomteux O, Detry R, Dahan K, Sempoux C. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Human pathology. 2011; 42(12):1897-910. https://doi.org/10.1016/j.humpath.2010.06.021 PMid:21665242
Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes & diseases. 2015; 2(1):4-12. https://doi.org/10.1016/j.gendis.2014.10.002 PMid:25815366 PMCid:PMC4372129
Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Annals of surgical oncology. 2013; 20(7):2166-71. https://doi.org/10.1245/s10434-013-2910-0 PMid:23456389 PMCid:PMC5584556
Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer cell. 2014; 25(3):304-17. https://doi.org/10.1016/j.ccr.2014.01.021 PMid:24651012 PMCid:PMC3970583
Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Molecular and cellular biology. 2007; 27(23):8284-95. https://doi.org/10.1128/MCB.00050-07 PMid:17908790 PMCid:PMC2169174
How to Cite
Copyright (c) 2019 Meike Rachmawati, Herry Yulianti, Bethy S. Hernowo, Sri Suryanti, Indra Wijaya, Nur Rahadiani, Didik S. Heriyanto, Irianiwati Irianiwati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.